Business
Ventripoint Diagnostics Announces U.S. FDA Clearance for VMS+ 3.0 Whole Heart Analysis System
(via TheNewswire) Toronto, Ontario - TheNewswire - October 17, 2019 - Vent...
About this update from Ventripoint Diagnostics Ltd.
[{"type":"text","content":"Ventripoint Diagnostics Announces U.S. FDA Clearance for VMS+ 3.0 Whole Heart Analysis System(via TheNewswire)\n \n \nToronto, Ontario - TheNewswire - October 17, 2019 - Ventripoint Diagnostics Ltd. (\"Ventripoint\" or the \"Company\"), (TSXV:VPT), (OTC:VPTDF) is pleased to announce that they have received U.S. Food and Drug Administration (FDA) clearance for the VMS+ 3.0 whole heart analysis system. \n\n\n \nThe VMS+ 3.0 system connects to standard echocardiography machines, the most widely used cardiac imaging technology globally. The system uses a proprietary Knowledge Based Reconstruction (KBR) technology creating 3D images of the heart and calculates volumes and ejection fraction for all 4 cardiac chambers with accuracy equivalent to MRI. The system can reduce the need for MRI in pediatrics and adults. \n\n\n \n\"We are thrilled that our innovative heart analysis system can now be used in hospitals across the United States. Millions of echocardiograms are performed in the US annually and our goal is to become the premier analysis tool for cardiac imaging in both pediatric and adult hospitals,\" commented Dr. George Adams, Ventripoint's CEO. \n\n\n \nEach year, $200 Billion is spent on heart disease in the US alone (Centers for Disease Control and Prevention). With heart disease being one of the leading causes of death for both men and women worldwide, accurate cardiac measurements are critical for patient care.\n\n\n \nThe VMS+ 3.0 system also has a Health Canada License and CE Marking (for the EU). \n\n\n \nAbout Ventripoint Diagnostics Ltd.\n\n\n \nVentripoint's technology is a leading Artificial Intelligence (AI) approach known as Knowledge-Based Reconstruction (KBR), used to create applications to monitor heart disease, a leading cause of death worldwide. The VMS+ is the first cost-effective and accurate tool for measuring whole heart function using conventional ultrasound. The Company has developed a suite of applications for all major heart diseases and is actively commercializing the approach to improve cardiac care. For further information please contact:\n\n\n \nDr. George Adams, CEO\nTelephone: (519) 803-6937\n\n\n \nEmail: [email protected]\n\n\n \nForward Looking Statements:\n\n\n \nThis news release contains forward-looking statements and forward-looking information within the meaning of applicable securit...